Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:00604257 | Esophagus | ESCC | lung morphogenesis | 37/8552 | 50/18723 | 4.42e-05 | 3.51e-04 | 37 |
GO:19043532 | Esophagus | ESCC | regulation of telomere capping | 22/8552 | 26/18723 | 4.88e-05 | 3.83e-04 | 22 |
GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
GO:00488638 | Esophagus | ESCC | stem cell differentiation | 122/8552 | 206/18723 | 5.95e-05 | 4.59e-04 | 122 |
GO:00456007 | Esophagus | ESCC | positive regulation of fat cell differentiation | 46/8552 | 66/18723 | 6.72e-05 | 5.11e-04 | 46 |
GO:004668619 | Esophagus | ESCC | response to cadmium ion | 47/8552 | 68/18723 | 7.81e-05 | 5.80e-04 | 47 |
GO:003087914 | Esophagus | ESCC | mammary gland development | 85/8552 | 137/18723 | 8.11e-05 | 6.01e-04 | 85 |
GO:009858613 | Esophagus | ESCC | cellular response to virus | 56/8552 | 84/18723 | 8.20e-05 | 6.01e-04 | 56 |
GO:00341984 | Esophagus | ESCC | cellular response to amino acid starvation | 34/8552 | 46/18723 | 9.39e-05 | 6.70e-04 | 34 |
GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
GO:00483083 | Esophagus | ESCC | organelle inheritance | 14/8552 | 15/18723 | 1.47e-04 | 9.85e-04 | 14 |
GO:00483133 | Esophagus | ESCC | Golgi inheritance | 14/8552 | 15/18723 | 1.47e-04 | 9.85e-04 | 14 |
GO:00485386 | Esophagus | ESCC | thymus development | 33/8552 | 45/18723 | 1.54e-04 | 1.02e-03 | 33 |
GO:007135620 | Esophagus | ESCC | cellular response to tumor necrosis factor | 132/8552 | 229/18723 | 1.69e-04 | 1.11e-03 | 132 |
GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
GO:00075699 | Esophagus | ESCC | cell aging | 81/8552 | 132/18723 | 2.00e-04 | 1.27e-03 | 81 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
MAPK1 | CD8TEXINT | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.57e-01 | |
MAPK1 | CD8TEREX | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.43e-01 | |
MAPK1 | MAIT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.38e-01 | |
MAPK1 | CD8TEREX | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.84e-01 | |
MAPK1 | CD8TEXINT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.00e-01 | |
MAPK1 | CD8TEREX | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 6.38e-02 | |
MAPK1 | TREG | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 1.20e-01 | |
MAPK1 | TH17 | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 8.39e-02 | |
MAPK1 | CD8TEREX | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 2.37e-01 | |
MAPK1 | MAIT | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 1.13e-01 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK1 | SNV | Missense_Mutation | | c.241G>A | p.Glu81Lys | p.E81K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
MAPK1 | SNV | Missense_Mutation | rs747124623 | c.994G>A | p.Asp332Asn | p.D332N | P28482 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MAPK1 | insertion | Frame_Shift_Ins | novel | c.1024_1025insTTGTGAGCCAAGGTAGAAGCAGTTGCTGGGGAGATGC | p.Lys342IlefsTer20 | p.K342Ifs*20 | P28482 | protein_coding | | | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
MAPK1 | SNV | Missense_Mutation | | c.961G>A | p.Asp321Asn | p.D321N | P28482 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.404G>A | p.Arg135Lys | p.R135K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PROGESTERONE | PROGESTERONE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | SPINASAPONIN A METHYL ESTER | SPINASAPONIN A METHYL ESTER | 20951582 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | TREQUINSIN HYDROCHLORIDE | TREQUINSIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | BENZOTHIAZOL-2-YLAMINE | CHEMBL329785 | 22982122 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PHENETHYLISOTHIOCYANATE | PHENETHYLISOTHIOCYANATE | 22607231 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | GENTIAN VIOLET | GENTIAN VIOLET | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | MITOXANTRONE DIHYDROCHLORIDE | MITOXANTRONE HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | ZM-449829 | CHEMBL154580 | |